AU
ALNY icon

AlphaGrep UK’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaGrep UK’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$489K Buy
1,623
+662
+69% +$200K 0.15% 248
2026
Q1 		$318K Sell
961
-895
-48% -$305K 0.09% 477
2025
Q4 		$738K Buy
+1,856
New +$821K 0.25% 84

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AlphaGrep UK's ALNY Position: Q2 2026 in Review

AlphaGrep UK increased its Alnylam Pharmaceuticals (ALNY) stake by 69% in Q2 2026, buying an estimated $200K and bringing the position to 1,623 shares worth $489K. The position accounts for 0.15% of the portfolio, ranked #248.

AlphaGrep UK first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $738K in Q4 2025. 733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • AlphaGrep UK held 1,623 shares of Alnylam Pharmaceuticals worth $489K as of Q2 2026.
  • AlphaGrep UK bought 662 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $200K.
  • Alnylam Pharmaceuticals made up 0.15% of AlphaGrep UK's portfolio in Q2 2026, its #248 holding.
  • AlphaGrep UK first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • AlphaGrep UK's Alnylam Pharmaceuticals position peaked at $738K in Q4 2025.
  • 733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.